Gastrointestinal tumors
Conditions
Interventions
ALA (10-20mg/kg) is administered orally 3-4 hours before endoscopy. Using a fluorescence detection system with violet laser diode (VLD-EX)
Sponsors
National Cancer Center Hospital
The Jikei University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) =>20 years old, <=85 years old. 2) Treatment is scheduled for the lesion. Without distinction the size. 3) Adapted estimated depth for endoscopic treatment case. 4) Endoscopic treatments are including EMR, hybrid EMR, ESD, EMRC, etc. Excluding ablation. 5) Within 60 days of study initiation. WBC => 3,500/mm3 Hb => 8.5 g/dl Plt => 100,000/mm3 T-bil <= 1.5 mg/dl AST (GOT) <= 100 IU/l ALT (GPT) <= 100 IU/l Cr <= 1.2mg/dl 7) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who can not intake oral medicine. 2) A history of photosensitivity. 3) Porphyria. 4) With malignant hypertension and severe congestive heart failure. Past history of myocardial infraction within the last three months. 5) Poor control of diabetes mellitus. 6) With severe pulmonary fibrosis and acute interstitial pneumonia. 7) Poor control of infection. 8) Patient taking anticoagulants and antiplatelet agents. 9) Patient receiving ferrotherapy. 10) Participating in the study of other division. 11) Patient who is difficult to understand the informed consent. 12) Woman during pregnancy or breast-feeding. 13) Patient is judged to be inappropriate for study participation for any reason by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection and visibility of gastrointestinal tumors after oral administration of ALA | — |
Countries
Japan
Contacts
Public ContactEriko So
National Cancer Center Hospital Endoscopy division
Outcome results
None listed